- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT07941947
Atrial Coronary Circulation in STEMI Patients With Newly Diagnosed Atrial Fibrillation (ACC-AF-STEMI)
Atrial Coronary Circulation in STEMI Patients With Newly Diagnosed Atrial Fibrillation (ACC-AF-STEMI)
This multicenter, prospective, observational, comparative cohort study will investigate the association between atrial coronary artery involvement and newly diagnosed atrial fibrillation (AF) in patients with ST-segment elevation myocardial infarction (STEMI).
Patients with acute STEMI undergoing coronary angiography will be assigned to two observational cohorts according to the development of AF during the first 24 hours of hospitalization: patients with a first-ever episode of AF and patients without AF, with the latter group matched by age and sex. Coronary angiograms will be assessed for thrombosis or stenosis of the arteries supplying the atria and for their relationship to the infarct-related artery.
The primary endpoint is the incidence of atrial coronary artery involvement in patients with newly diagnosed AF during acute STEMI. Secondary endpoints include all-cause and cardiovascular mortality, acute heart failure, thromboembolic complications, major bleeding, duration of hospitalization and intensive care stay, AF recurrence, cardioversion, and prescription of direct oral anticoagulants during hospitalization.
The study plans to enroll 400 participants, with 200 patients in each cohort. The study is non-interventional, and all diagnostic and therapeutic procedures will be performed according to standard clinical care. The follow-up will include the index hospitalization and a 30-day telephone assessment.
Studie Overzicht
Toestand
Interventie / Behandeling
Gedetailleerde beschrijving
Atrial fibrillation (AF) is a common complication of acute ST-segment elevation myocardial infarction (STEMI) and is associated with adverse clinical outcomes, including acute heart failure, thromboembolic complications, prolonged hospitalization, and increased mortality. Despite advances in reperfusion therapy and contemporary STEMI management, the mechanisms underlying the development of newly diagnosed AF during acute STEMI remain incompletely understood. In particular, the potential role of the coronary arteries supplying the atrial myocardium has not been sufficiently characterized.
The ACC-AF-STEMI study is a multicenter, prospective, observational, comparative cohort study designed to investigate the association between atrial coronary artery involvement and the development of de novo AF during acute STEMI. The scientific hypothesis is that thrombosis or atherosclerotic lesions of the arteries supplying the atria, particularly when these vessels are related to the infarct-related artery, may contribute to the development of AF during the acute phase of STEMI.
Patients with a verified diagnosis of STEMI who undergo coronary angiography will be prospectively enrolled. Participants will be divided into two observational cohorts according to the development of AF during the first 24 hours of hospitalization. The main cohort will include patients with a first-ever episode of AF occurring during acute STEMI. The comparison cohort will include patients with STEMI who do not develop AF during hospitalization and will be matched by age and sex.
The key study procedure is systematic assessment of coronary angiograms. In addition to evaluation of the infarct-related artery and multivessel coronary disease, the angiographic analysis will assess thrombosis or stenosis of the arteries supplying the atria, including the right ostial/conus-related atrial branches (ROCS), atrioventricular nodal artery (AVNA), right inferior atrial artery (RIAA), and left inferior atrial artery (LIAA), as specified in the protocol. Their origin and relationship to the infarct-related artery, as well as TIMI flow before and after percutaneous coronary intervention (PCI), will be documented. Angiographic assessment will be performed by a specialized angiography committee blinded to the patient's AF status in order to minimize assessment bias.
AF will be identified using continuous electrocardiogram (ECG) monitoring during the initial intensive care unit (ICU) period, daily 12-lead ECGs, and recording of symptomatic episodes. Echocardiographic assessment will include left atrial volume index, mitral regurgitation, left ventricular ejection fraction according to the Simpson method, pulmonary artery systolic pressure, and E/E'. Clinical, laboratory, ECG, echocardiographic, angiographic, procedural, and treatment data will be prospectively recorded in an electronic case report form.
The primary endpoint is the incidence of atrial coronary artery involvement in patients with newly diagnosed AF during acute STEMI. Secondary endpoints include all-cause mortality, cardiovascular mortality, development of acute heart failure (Killip class ≥ II), thromboembolic complications including stroke and pulmonary embolism, and major bleeding defined as Bleeding Academic Research Consortium (BARC) grade ≥3. Additional outcomes include duration of hospitalization and ICU stay, type and number of cardioversions, recurrence of AF during hospitalization, failure to restore sinus rhythm, and prescription of direct oral anticoagulants during hospitalization.
The planned target sample size is 400 patients, with 200 participants in each cohort. The protocol's sample-size calculation was based on an expected difference in atrial coronary artery involvement between patients with STEMI and newly diagnosed AF and those without AF. The larger target sample is intended to support multivariable analysis and account for potential technical limitations in angiographic assessment and the relatively low prevalence of AF among patients with STEMI.
Patient recruitment is planned over 12 months. Each participant will be followed during the index hospitalization, with assessment of acute clinical outcomes, and will additionally undergo a 30-day telephone follow-up. The study is planned as a multicenter and multinational investigation, with the Samara Regional Clinical Cardiology Dispensary named after V.P. Polyakov serving as the initiating center and additional PCI-capable hospitals participating through the STEMI network.
The study is non-interventional. Coronary angiography, PCI, pharmacological treatment, cardioversion, anticoagulant therapy, and other diagnostic or therapeutic procedures will be performed solely according to clinical indications and applicable standards of care. Participation in the study does not determine or modify the treatment received by patients.
Safety information, including serious adverse events occurring from coronary angiography through hospital discharge and during the 30-day follow-up period, will be recorded. Events of particular interest include procedure-related death, stroke, major bleeding, acute kidney injury, coronary artery perforation or aortic dissection, emergency сoronary artery bypass grafting (CABG), thromboembolic complications, severe bradycardia or sinus arrest requiring temporary pacing, and cardiac tamponade.
The study is intended to improve understanding of the relationship between atrial coronary artery involvement and newly diagnosed AF during acute STEMI and to characterize the clinical and angiographic features associated with this complication.
Studietype
Inschrijving (Geschat)
Contacten en locaties
Studiecontact
- Naam: Dmitry V. Duplyakov
- Telefoonnummer: +79277297273
- E-mail: duplyakov@yahoo.com
Studie Contact Back-up
- Naam: Larisa Shekhovtsova
- Telefoonnummer: +79524299333
- E-mail: shekhovtsova_l@mail.ru
Studie Locaties
-
-
-
Samara, Rusland, 443070
- Samara Regional Cardiology Dispansery
-
Contact:
- Dmitry V. Duplyakov, MD, PhD
- Telefoonnummer: +79277297273
- E-mail: duplyakov@yahoo.com
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Bemonsteringsmethode
Studie Bevolking
Adults with acute ST-elevation myocardial infarction (STEMI) admitted within 24 hours of symptom onset and undergoing coronary angiography with or without percutaneous coronary intervention (PCI). The study includes patients with no previous history of atrial fibrillation who either develop first-ever atrial fibrillation within the first 24 hours of hospitalization or remain free of atrial fibrillation during hospitalization. The comparison cohort is matched by age and sex.
Beschrijving
Inclusion Criteria:
- Main cohort - STEMI patients with newly diagnosed atrial fibrillation: Age 18-75 years. ST-elevation myocardial infarction (STEMI) with symptom onset within 24 hours before enrollment.
No history of atrial fibrillation before the index STEMI. First-ever episode of atrial fibrillation documented within the first 24 hours of hospitalization.
Coronary angiography with or without percutaneous coronary intervention (PCI). Written informed consent.
- Control cohort - STEMI patients without atrial fibrillation:
Age ≥18 years. STEMI with symptom onset within 24 hours before enrollment. No history of atrial fibrillation before the index STEMI. No first-ever episode of atrial fibrillation during hospitalization. Coronary angiography with or without PCI. Written informed consent.
Exclusion Criteria:
- Known history of AF prior to STEMI.
- Time from onset of STEMI symptoms > 24 hours.
- Chronic Obstructive Pulmonary Disease stage ≥2.
- History of Myocardial Infarction.
- History of previous PCI or CABG.
- History of Valve Surgery.
- Mitral or Tricuspid Valve insufficiency grade ≥ 2.
- Hemodynamically significant Mitral Stenosis (<1.5 cm2).
- Permanent pacemaker.
- Malignancy in the active treatment phase or terminal cancer.
- Severe comorbidities (e.g., end-stage CKD, cirrhosis) with a life expectancy of less than 1 year.
- Known thyrotoxicosis.
- Non-invasive treatment strategy.
- Patient's refusal to participate in the study.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Observatiemodellen: COHORT
- Tijdsperspectieven: PROSPECTIVE
Cohorten en interventies
Groep / Cohort |
Interventie / Behandeling |
|---|---|
|
STEMI With Newly Diagnosed Atrial Fibrillation
Patients with STEMI who develop a first-ever episode of atrial fibrillation during the first 24 hours of hospitalization. Patients have no history of atrial fibrillation before STEMI and undergo coronary angiography with or without subsequent PCI. |
Presence of thrombosis and/or stenosis of atrial coronary artery branches (ROCS, AVNA, RIAA, and LIAA), including their relationship to the infarct-related artery and TIMI flow, assessed by coronary angiography. This exposure is not assigned by the study investigators and is observed during standard-of-care coronary angiography. |
|
STEMI Without Atrial Fibrillation
Patients with STEMI who do not develop atrial fibrillation during hospitalization. Patients have no history of atrial fibrillation before STEMI and undergo coronary angiography with or without subsequent PCI. The comparison cohort is matched by age and sex. |
Presence of thrombosis and/or stenosis of atrial coronary artery branches (ROCS, AVNA, RIAA, and LIAA), including their relationship to the infarct-related artery and TIMI flow, assessed by coronary angiography. This exposure is not assigned by the study investigators and is observed during standard-of-care coronary angiography. |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Incidence of atrial coronary artery involvement in patients with newly diagnosed atrial fibrillation during acute STEMI
Tijdsspanne: At the time of coronary angiography
|
Atrial coronary artery involvement is defined as the presence of thrombosis and/or stenosis of atrial coronary artery branches (ROCS, AVNA, RIAA, and LIAA), including assessment of their relationship to the infarct-related artery and TIMI flow, as determined by coronary angiography. |
At the time of coronary angiography
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
All-cause mortality
Tijdsspanne: On discharge from the hospital, an average of 14 days
|
Death from any cause during hospitalization |
On discharge from the hospital, an average of 14 days
|
|
Cardiovascular mortality
Tijdsspanne: On discharge from the hospital, an average of 14 days
|
Death from cardiovascular disease during hospitalization |
On discharge from the hospital, an average of 14 days
|
|
Acute heart failure, Killip class II or higher
Tijdsspanne: On discharge from the hospital, an average of 14 days
|
Development of acute heart failure (Killip stage ≥ II) |
On discharge from the hospital, an average of 14 days
|
|
Thromboembolic complications
Tijdsspanne: On discharge from the hospital, an average of 14 days
|
Development of thromboembolic complications (stroke, pulmonary embolism) |
On discharge from the hospital, an average of 14 days
|
|
Major bleeding, BARC grade 3 or higher
Tijdsspanne: On discharge from the hospital, an average of 14 days
|
Bleeding (BARC score ≥ 3) |
On discharge from the hospital, an average of 14 days
|
Medewerkers en onderzoekers
Studie record data
Bestudeer belangrijke data
Studie start (Geschat)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- SamaraSOKKD_1
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .